Digoxin is a drug that is commonly used to treat congestive heart failure. Because of digoxin's narrow therapeutic index, patients are susceptible to drug-drug interaction-mediated cardiotoxicity. Digoxin is primarily cleared renally; however, a significant component of clearance is due to multidrug resistance 1-mediated transport into bile. Digoxin is reported to be actively transported into human hepatocytes by the organic anion-transporting polypeptide 1B3 (OATP1B3); however, further characterization has not been fully described. 
Introduction
Transporter-mediated uptake of drugs in the liver can be a major determinate of hepatic clearance. Members of the solute carrier superfamily of transporters mediate the majority of hepatic drug uptake in humans. These transporters include organic anion-transporting polypeptides OATP1B1 (SLCO1B1), OATP1B3 (SLCO1B3), and OATP2B1 (SLCO2B1), the organic anion transporter OAT2 (SLC22A7), and the organic cation transporter OCT1 (SLC22A1). Of these, the OATP transporters are the most relevant for uptake of drugs into the liver. In addition to the role uptake transporters play in defining hepatic clearance, researchers have also recognized that inhibition of uptake transporters can reduce hepatic drug clearance, and this inhibition represents a potential source of drug-drug interactions (DDIs) (Shitara et al., 2003; Poirier et al., 2007) . For these reasons, it is important to identify the contribution of transporters to the overall uptake of drugs and to identify the specific transporter(s) involved.
Digoxin is a cardiac glycoside that is commonly used in clinical practice to treat congestive heart failure (Gheorghiade and Pitt, 1997) .
Digoxin has a narrow therapeutic range and has been associated with numerous drug interactions with coadministered drugs (Koren, 1985; Rodin and Johnson, 1988) ; consequently, patients can be particularly susceptible to DDI-mediated cardiotoxicity. Digoxin is primarily eliminated in urine; however, 30 to 50% is cleared via the liver (Goodman and Gilman, 2006) . Digoxin is a substrate for the efflux transporter multidrug resistance 1 (MDR1/ABCB1) and is the recognized probe substrate to assess MDR1 DDI in the clinic (U.S. Food and Drug Administration, http://www.fda.gov/downloads/drugs/guidance complianceregulatoryinformation/guidances/ucm072101.pdf). Evidence suggests that digoxin is primarily taken up actively into both rat and human hepatocytes. In rats, hepatic disposition of digoxin has been fairly well characterized. Digoxin has been shown to be a substrate of rat Oatp1a4 (Noé at al., 1997; Kodawara et al., 2002) and mouse Oatp1a4 (Ose et al., 2010) , and hepatocyte uptake K m values range from 0.18 to 36 M (Hedman and Meijer, 1998; Lam and Benet, 2004; Liu et al., 2005) . In human hepatocytes, digoxin uptake is decreased by 95% at 4°C (Olinga et al., 1998) . It has also been reported that digoxin is a substrate for OATP1B3 using Xenopus laevis oocytes (Kullak-Ublick et al., 2001) . However, further characterization of digoxin uptake into human hepatocytes has not been fully described.
Sandwich-cultured hepatocytes form intact bile canalicular networks, and they maintain functional expression levels of uptake and efflux transporter proteins for several days (Hoffmaster et al., 2004; Li et al., 2009) . We previously reported the ability to use cryopreserved human hepatocytes in sandwich culture (Bi et al., 2006) and have shown that uptake and efflux transporter activities are similar to those in fresh hepatocytes. The purpose of this study was to investigate the hepatic uptake of digoxin using cryopreserved human hepatocytes in sandwich culture.
Uptake Study in Sandwich-Cultured Human Hepatocytes. The incubation medium used for the uptake study was Ca 2ϩ -containing HBSS buffer. After rinsing the cells twice with Ca 2ϩ HBSS buffer, they were preincubated for 10 min at 37°C or 4°C with Ca 2ϩ HBSS buffer in the absence or presence of inhibitors. After aspirating the buffer, 0.5 ml of incubation buffer containing a substrate in the absence or presence of inhibitors was added at 37°C or 4°C. The uptake was terminated at a designated time by adding 0.5 ml of ice-cold Ca 2ϩ HBSS buffer after removal of the incubation buffer. Cells were then quickly washed three times with 0.5 ml of ice-cold Ca 2ϩ HBSS buffer, then solubilized with 0.5 ml of 0.5% Triton X-100 in Dulbecco's phosphatebuffered saline. After shaking plates, aliquots (0.5 ml) were transferred to scintillation vials. Radioactivity was measured by a liquid scintillation counter (Wallac 1409 DSA; PerkinElmer Life and Analytical Sciences) after adding 6 ml of scintillation fluid (Ready Safe; Beckman Coulter) to the scintillation vials. For determination of digoxin uptake kinetics, various concentrations of [ 3 H]digoxin (0.05-300 M) were incubated for 5 min at 37°C as described above. Data were then fit to eq. 1 using GraphPad Prism (GraphPad Software Inc., San Diego, CA), where P dif represents nonsaturable or passive diffusion in units of l/(min ⅐ mg protein).
Transport Study in Transfected HEK293 Cells. Studies with the three hepatic transporters (OATP1B1, OATP1B3, and OATP2B1) were conducted based on a previously described method (Kalgutkar et al., 2007) . Human OATP1B1 and OATP1B3 expressed in HEK293 cells were obtained from Prof. Yuichi Sugiyama (University of Tokyo, Tokyo, Japan), and human OATP2B1 expressed in HEK293 cells were obtained from Prof. Dietrich Keppler (DKFZ, Heidelberg, Germany). In brief, transporter-transfected and wild-type HEK293 cells were seeded onto 24-well poly-D-lysine-coated plates at a density of ϳ2.5 ϫ 10 5 cells per well. OATP2B1-transfected cells were cultured with 10 mM sodium-N-butyrate 24 h before conducting the transporter assay. OATP1B3-transfected cells were cultured with and without 10 mM sodium-N-butyrate for 24 h before conducting the transporter assays. After the cells were confluent, they were washed three times with 1 ml of uptake buffer. The transport study was initiated by incubation of the cells with 0.3 ml of incubation buffer containing each test compound in the absence or presence of inhibitors at 37°C. At the completion of the incubation, transport was stopped by washing the cells three times with ice-cold buffer. The cells were then lysed in 1% SDS and 0.1 M NaOH in water, and the radioactivity was measured by liquid scintillation spectroscopy.
Transport Study in X. laevis Oocytes. OATP1B3*1- (König et al., 2000) and water-injected oocytes and a reagent pack were purchased from BD Biosciences. Oocytes were used 5 days after injection, and then the transport study was conducted at room temperature. All uptake studies were performed in Na ϩ buffer from a reagent pack containing 100 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , and 10 mM HEPES buffer adjusted to pH 7.4. Eight to 10 oocytes were prewashed in 3 ml of uptake buffer three times and then incubated at room temperature in 0.1 ml of uptake buffer containing each test compound at the indicated concentrations. Water-injected oocytes were used as controls for nonspecific uptake and binding of the test compound. Uptake was stopped by adding 3 ml of ice-cold uptake buffer, and oocytes were washed three times in 3 ml of ice-cold uptake buffer. Individual oocytes were transferred to scintillation vials and lysed in 0.15 ml of 10% SDS in uptake buffer. Radioactivity was measured by liquid scintillation spectroscopy. Statistical Analysis. Two methods were used to assess the statistical significance of differences, depending upon the type of data being analyzed. One method was to use an unpaired two-tailed Student's t test for data generated in single studies with vehicle control and treatment groups. For data generated over multiple studies, each including vehicle control and treatment groups, an analysis of variance was conducted within each study, and then all treatments were compared versus control using Dunnett's procedure. A value of p Ͻ 0.05 was predetermined as the criterion for significance for both statistical methods.
Results

Time Course of Digoxin Uptake in Sandwich-Cultured Human
Hepatocytes. The time course of digoxin uptake into sandwichcultured human hepatocytes (SCHH) is shown in Fig. 1 . The uptake of digoxin increased linearly up to 5 min. Digoxin uptake showed significant temperature dependence. The uptake rate over 5 min at 37°C was 153 fmol/(min ⅐ mg protein), whereas the uptake rate at 4°C was only 1.33 fmol/(min ⅐ mg protein).
Uptake Kinetics of Digoxin in SCHH. To characterize the uptake kinetics of digoxin, the concentration dependence of uptake into SCHH was examined. The uptake of digoxin was characterized as having a saturable component at low concentrations and a nonsaturable or passive component at high concentrations (Fig. 2, A and B) . In the concentration range 0.05 to 10 M, uptake followed MichaelisMenten kinetics with a K m of 2.39 M and a V max of 4.49 pmol/(min ⅐ mg protein), which results in an uptake clearance of 1.88 l/(min ⅐ mg protein). Using eq. 1, the calculated passive diffusion clearance was significant at 1.25 l/(min ⅐ mg protein) and represents 40% of total uptake clearance.
Inhibitory Effect of Various Compounds on the Uptake of Digoxin in SCHH.
To characterize the saturable uptake transport mechanism of digoxin, an extensive study was undertaken to assess the potential of a wide variety of known transporter substrates and inhibitors to affect the uptake of digoxin (Table 1 ). The uptake of digoxin in SCHH was not inhibited by classic OATP substrates and inhibitors, including bromosulfophthalein (BSP), which has recently been shown to also be an inhibitor of monocarboxylate transporter 8 (Kinne et al., 2010) . Digoxin uptake was also not affected by a high concentration of the OATP1B3 substrate CCK-8. In addition, neither ES, 4,4Ј-diisothiocyanostilbene-2,2Ј-disulfonic acid, p-aminohippuric acid, probenecid, nor quinidine inhibited digoxin uptake. The mitochondrial uncouplers carbonyl cyanide-m-chlorophenylhydrazone and 2,4-dinitrophenol did not inhibit digoxin uptake, whereas carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) appeared to have a weak, yet variable, inhibitory effect. The antiarrhythmic agents amiodarone [known to elicit a nonrenal DDI with digoxin in humans (Nademanee et al., 1984) ] and quinidine (an OCT1 inhibitor) had no effect on the uptake of digoxin in SCHH. Although the glucose transporter (GLUT) inhibitor cytochalasin B did not inhibit digoxin uptake, the known GLUT2 inhibitor quercetin and its glycosylated analog rutin (quercetin-3-rutinoside) did show inhibition of digoxin uptake. The cardiac glycosides digoxin (unlabeled) and ouabain also inhibited the uptake of [ 3 H]digoxin. The inhibitory effects of several compounds in a different cryopreserved hepatocyte lot are shown in Table 2 . In lot Hu4165, the classic OATP inhibitors cyclosporine A (CsA), BSP, and rifampicin did not inhibit digoxin uptake. FCCP had a modest inhibitory effect, and nonlabeled digoxin inhibited the uptake of [ 3 H]digoxin by ϳ50%. All compounds (CsA, BSP, FCCP, rifampicin, and digoxin) significantly inhibited the uptake of the known OATP1B3 substrate CCK-8.
Uptake Clearance of Digoxin and CCK-8 in Suspension and SCHH. The uptake clearance of digoxin in SCHH was compared to that observed in hepatocyte suspensions. As seen in Table 3 1, 2, 10, 20, 40, 80, 100, 140, 180, 200, 250 , and 300 M at 37°C (A), and kinetics were determined at 0.05, 0.1, 0.2, 1, 2, and 10 M at 37°C (B). Each experimental point represents the mean Ϯ S.D. of 3 to 6 measurements from 1 or 2 studies in human hepatocyte lot 109. Data were modeled using eq. 1 as described under Materials and Methods. in suspensions. In addition, day 5 SCHH retained appreciable OATP1B3-specific activity relative to suspensions, as evidenced by the uptake clearance of CCK-8. In hepatocyte suspensions, 100 M rifamycin SV did not affect digoxin uptake clearance, whereas CCK-8 uptake clearance was inhibited 86%.
Uptake of Substrates and Digoxin by OATP1B1, OATP1B3, and OATP2B1-Transfected Cells. Table 4 lists the transfected/wildtype uptake ratios obtained for various substrates using OATP-expressing HEK293 cells. OATP1B1 mediated ES and rosuvastatin transport, although it did not transport digoxin or the negative control, midazolam. OATP1B3 efficiently mediated E-17␤-G, CCK-8, and rosuvastatin transport, but the uptake of digoxin by OATP1B3 was much lower and similar to that observed for the negative control midazolam. OATP2B1 efficiently mediated ES and rosuvastatin transport, whereas it did not show uptake of digoxin.
The Effect of Rifamycin SV on the Uptake of Digoxin by OATP1B3-Expressing HEK293 Cells. The effect of rifamycin SV on OATP1B3-mediated uptake was determined (Fig. 3) . The uptake of E-17␤-G into OATP1B3-expressing HEK293 cells was 89-fold higher than that into wild-type HEK293 cells, and this uptake was nearly completely inhibited by 100 M rifamycin SV. The uptake of rosuvastatin into OATP1B3-expressing HEK293 cells was 9-fold higher than that into wild-type HEK293 cells. The uptake of rosuvastatin was significantly inhibited by 100 M rifamycin SV. The uptake of digoxin into OATP1B3-expressing HEK293 cells was very low (2.2-fold higher than that into wild-type cells), and 100 M rifamycin SV had no effect on the uptake of digoxin. Uptake of Substrates and Digoxin by X. laevis Oocytes Expressing OATP1B3*1. To further determine the potential role of OATP1B3 in digoxin uptake, we investigated uptake by X. laevis oocytes expressing OATP1B3*1 in the presence and absence of the OATP inhibitors CsA and rifamycin SV (Fig. 4) . OATP1B3-mediated uptake of E-17␤-G was 36-fold higher compared to water-injected oocytes. Two inhibitors, 10 M CsA and 100 M rifamycin SV, significantly inhibited the uptake of E-17␤-G. OATP1B3-mediated uptake of CCK-8 was 4.9-fold higher compared to water-injected oocytes, and both CsA and rifamycin SV significantly inhibited uptake. In studies 1 and 2, the uptake of digoxin was similar to that observed in water-injected oocytes. Neither CsA nor rifamycin SV inhibited digoxin uptake.
Discussion
The liver plays an important role in drug metabolism and excretion. It is well known that hepatic drug-drug interactions can affect the therapeutic safety and efficacy of drugs. Although digoxin has been widely used in humans for many years, its therapeutic index is very narrow and drug-drug interactions with this agent have been reported (Leahey et al., 1978; Moysey et al., 1981; Dorian et al., 1988) . Approximately 50 to 70% of digoxin is excreted in urine, whereas 30 to 50% is cleared by the liver, primarily via excretion of unchanged drug in bile (Goodman and Gilman, 2006) . The mechanism of digoxin hepatic uptake in humans is not well understood, especially as it pertains to transporter-mediated uptake.
In this study, we further characterized the hepatic uptake of digoxin by using cryopreserved human hepatocytes in sandwich-culture. Our data reveal two novel aspects of digoxin uptake: 1) there is a significant passive component of digoxin uptake in human hepatocytes, and 2) neither OATP nor any other known drug uptake transporter is involved in digoxin uptake. These findings are significant, and they have important implications on the interpretation of in vitro data to predict clinical outcomes as described below.
Our data show that uptake of digoxin is mediated by both saturable (carrier-mediated) and passive (or nonsaturable) processes. The passive contribution to uptake is significant, and represents 40 to 50% of total hepatic uptake, as evidenced by the high passive diffusion clearance relative to the total uptake clearance ( Fig. 2A) and the fact that very high concentrations of unlabeled digoxin could inhibit only ϳ50% of [ 3 H]digoxin uptake (Tables 1 and 2 ). Even though uptake of [ 3 H]digoxin is nearly completely inhibited at 4°C (Fig. 1) , the fact that very high concentrations of unlabeled digoxin could not inhibit more than ϳ50% of [ 3 H]digoxin uptake at 37°C strongly suggests that the lack of uptake at 4°C is an artifact of a more rigid plasma membrane. This artifact has been noted previously for propranolol (Webborn et al., 2007) . These examples highlight the caution one must use when interpreting uptake data at 37°C and 4°C.
Despite a significant passive component to digoxin uptake, a clinically relevant uptake transporter DDI with coadministered drugs is possible. Our data suggest that active or saturable uptake represents 50 to 60% of total uptake. When one couples this with the fact that ϳ40% of digoxin is eliminated via hepatic mechanisms (primarily via efflux into bile), the theoretical maximum fold increase in systemic area under the plasma concentration-time curve (AUC) due to complete inhibition of digoxin carrier-mediated uptake into liver would be ϳ1.3. Because digoxin has a narrow therapeutic index, an AUC or C max increase of Ն25% is considered significant (Zhang et al., 2008) . The two flavonoids, quercetin and rutin, showed significant inhibition of [ 3 H]digoxin uptake similar to that seen with unlabeled digoxin (ϳ50%). Both flavonoids are present in the human diet, and both are available as dietary supplements. These data suggest that high concentrations of flavonoids could also affect digoxin AUC levels due to inhibition of digoxin hepatic uptake.
Our study has clearly demonstrated that digoxin is not a substrate of OATP1B1, OATP1B3, or OATP2B1. First, several classic pan-inhibitors of OATPs had no effect on digoxin uptake in SCHH. Second, when using OATP-transfected HEK293 cells, we noted no significant uptake of digoxin, whereas known substrates of these transporters performed as expected in these assays. Even though digoxin exhibited uptake ratios in the range of 1.6 to 2.3 in OATP1B3-transfected cells ( Fig. 3; Table 4 ), these ratios were similar to those observed for the negative control midazolam, and rifamycin SV had no effect on digoxin uptake. Lastly, two separate studies with OATP1B3 oocytes showed no digoxin uptake compared to water-injected control oocytes. These two studies are in contrast to the previous study by Kullak-Ublick et al. (2001) , who reported an OATP1B3/control oocyte ratio of 2.4 for digoxin. The reason for this difference is not clear. However, the several approaches taken in the current study to assess the potential for OATP1B3-mediated uptake of digoxin clearly show that digoxin is not a substrate of OATP1B3 in transfected cells and in hepatocytes. Our data indicate that digoxin should not be used as a probe substrate for OATP1B3 in human hepatocyte systems. A previous clinical study suggested that an insert-variant allele of OATP1B3 was associated with an increase in the concentration/dose ratio of digoxin in patients on hemodialysis measured 62 to 72 h postdose (Tsujimoto et al., 2008) . Although this finding appears to support a role for OATP1B3-mediated hepatic clearance in patients on hemodialysis, additional studies comparing this allele with the measured digoxin systemic clearance are needed to confirm these findings.
This study has highlighted the utility of sandwich-cultured hepatocytes as a model to measure OATP-mediated uptake. We have previously shown that SCHH possess significant OATP activity (Bi et al., 2006) , and a previous study showed that OATP1B1 and OATP1B3 protein levels are well maintained on day 6 in SCHH (Hoffmaster et al., 2004) . Our data show that the uptake clearance of digoxin in sandwich culture is similar to that observed in noncultured hepatocyte suspension, and OATP1B3-specific activity (as measured by CCK-8 uptake clearance) is appreciable in sandwich culture. In addition, the effect of rifamycin SV on the uptake of digoxin and the OATP1B3-specific substrate CCK-8 is identical in suspensions and sandwich culture.
The only two compounds that showed significant inhibition of [ 3 H]digoxin uptake are the flavonoids quercetin and rutin. Each compound inhibited digoxin uptake by ϳ50% (Table 1 ). Both compounds have been shown to inhibit OATP2B1 (Satoh et al., 2005; Fuchikami et al., 2006) . Quercetin inhibits the major hepatic glucose transporter GLUT2 (Thorens et al., 1990; Song et al., 2002) , whereas rutin does not (Song et al., 2002) . Rutin has been shown to increase the activity of OATP1B1, whereas quercetin had no effect on this transporter . Even though these two flavonoids interact with OATP1B1 and OATP2B1, our results show that digoxin uptake is not due to these transporters. Although the data are limited, it is interesting to speculate that physiochemical properties of flavonoids may be important for an interaction with the putative digoxin transporter(s).
The results from this study also highlight differences in digoxin hepatic uptake between rats and humans. In contrast to the results (for humans) reported here, which show digoxin is not a substrate of hepatic OATPs, it has been shown that digoxin is a substrate of hepatic Oatp1a4 in rats (Noé et al., 1997) , although there is no ortholog of Oatp1a4 in humans. In addition, amiodarone, quinidine, and rifampicin have been shown to inhibit uptake of digoxin in rat hepatocytes (Lambert et al., 1989; Hedman and Meijer, 1998; Olinga et al., 2001; Kodawara et al., 2002; Lam and Benet, 2004; Lau et al., 2004) . None of these compounds inhibited digoxin uptake in SCHH in the current study. A species difference for digoxin metabolism is well documented; digoxin is not significantly metabolized in humans, whereas CYP3A-mediated metabolism in rats is substantial (Salphati and Benet, 1999) . Thus, the data suggest there are significant differences in the hepatic disposition of digoxin between rats and human. In rats, digoxin active uptake is mediated by Oatp1a4 and digoxin undergoes significant hepatic metabolism. In humans, digoxin uptake is not mediated by OATP1B1, OATP1B3, and OATP2B1 and very little hepatic metabolism occurs. Both species excrete digoxin into bile via MDR1/Mdr1, however (Annaert et al., 2001; Pauli-Magnus et al., 2001; Taipalensuu et al., 2004) .
In conclusion, the results of this study have highlighted important aspects of digoxin uptake in human hepatocytes and are consistent with a significant passive component (40 -50%) to digoxin uptake into human hepatocytes. The saturable (carrier-mediated) component of digoxin uptake does not involve typical hepatic drug transporters, such as OATP1B1, OATP1B3, OATP2B1, OAT2, and OCT1. Consequently, drugs that only interact with one or more of these transporters would not be expected to affect digoxin blood concentrations. However, because of digoxin's narrow therapeutic index, drugs or dietary supplements that potently inhibit the putative digoxin transporter(s) responsible for its carrier-mediated uptake could lead to a clinically relevant DDI. More work is needed to identify the transporter(s) involved in the hepatic uptake of digoxin. Despite conflicting data on the role of GLUT2 in transporting digoxin (cytochalasin B did not affect uptake, but quercetin inhibited uptake by ϳ50%), future studies should focus on the putative role of GLUT2 by testing additional inhibitors in hepatocytes and in GLUT2-transfected cell models. In addition, due to the significant effect flavonoids appear to have on digoxin uptake, it would be of interest to test additional dietary flavonoids for their effect on digoxin uptake.
